Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: Experience of the European Synergo® working party

World Journal of Urology

Volumn 27, Issue 3, 2009, Pages 319-324

  Alfred Witjes, J ^a   Hendricksen, Kees ^a   Gofrit, O ^b   Risi, O ^c   Nativ, O ^d  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c TREVIGLIO HOSPITAL   (Italy)

^d BNAI ZION MEDICAL CENTER   (Israel)

Author keywords

Bladder cancer; CIS; Hyperthermia; Mitomycin C; Thermochemotherapy

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; MITOMYCIN;

AGED; ARTICLE; BLADDER TUMOR; CARCINOMA IN SITU; CLINICAL TRIAL; EUROPE; FEMALE; HUMAN; HYPERTHERMIC THERAPY; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; RETROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA IN SITU; COMBINED MODALITY THERAPY; EUROPE; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; MALE; MIDDLE AGED; MITOMYCIN; RETROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS;

EID: 67349175605     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-009-0384-2     Document Type: Article

References (29)

1. Park J, Song C, Hong JH, Park BH, Cho YM, Kim CS, Ahn H (2009) Prognostic significance of non-papillary tumor morphology as a predictor of cancer progression and survival in patients with primary T1G3 bladder cancer. World J Urol. doi: 10.1007/s00345-008-0350-4
2. Sylvester RJ, van der Meijden AP, Oosterlinck W et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466-5. doi: 10.1016/ j.eururo.2005.12.031
3. Denzinger S, Fritsche HM, Otto W, Blana A, Wieland WF, Burger M (2008) Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: Do risk factors define feasibility of bladder-sparing approach? Eur Urol 53:146-152. doi: 10.1016/ j.eururo.2007.06.030
4. Shariat SF, Palapattu GS, Karakiewicz PI, Rogers CG, Vazina A, Bastian PJ, Schoenberg MP, Lerner SP, Sagalowsky AI, Lotan Y (2007) Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. Eur Urol 51:152-160. doi: 10.1016/j.eururo.2006.08.037
5. Griffiths TR, Charlton M, Neal DE, Powell PH (2002) Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. J Urol 167:2408-2412. doi: 10.1016/S0022-5347(05)64994-4
6. van der Meijden AP, Sylvester R, Oosterlinck W et al (2005) EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ. Eur Urol 48:363-371
7. Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, Wolf JS Jr, Schellhammer PF (2007) Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 178:2314-2330. doi: 10.1016/j.juro.2007.09.003
8. Witjes JA (2006) Management of BCG failures in superficial bladder cancer: A review. Eur Urol 49:790-797. doi: 10.1016/j.eururo.2006.01.017
9. Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M (2000) Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The valrubicin study group. J Urol 163:761-767. doi: 10.1016/ S0022-5347(05)67799-3
10. Dalbagni G, Russo P, Sheinfeld J et al (2002) Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol 20:3193-3198. doi: 10.1200/JCO.2002.02.066
11. Morales A (2008) Evolution of intravesical immunotherapy for bladder cancer: Mycobacterial cell wall preparation as a promising agent. Expert Opin Investig Drugs 17:1067-1073. doi: 10.1517/13543784.17.7.1067
12. O'Donnell MA, Krohn J, DeWolf WC (2001) Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J Urol 166:1300-1304. doi: 10.1016/S0022-5347(05)65757-6 (discussion)
13. Berger AP, Steiner H, Stenzl A, Akkad T, Bartsch G, Holtl L (2003) Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: A single-center study. Urology 61:338-341. doi: 10.1016/ S0090-4295(02)02123-4
14. Di Stasi SM, Giannantoni A, Giurioli A et al (2006) Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: A randomised controlled trial. Lancet Oncol 7:43-51. doi: 10.1016/S1470-2045(05)70472-1
15. Colombo R, Da Pozzo LF, Lev A, Freschi M, Gallus G, Rigatti P (1996) Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer. J Urol 155:1227-1232. doi: 10.1016/S0022-5347(01)66225-6
16. Colombo R, Da Pozzo LF, Salonia A et al (2003) Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 21:4270-4276. doi: 10.1200/JCO.2003.01.089
17. Gofrit ON, Shapiro A, Pode D et al (2004) Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Urology 63:466-471. doi: 10.1016/ j.urology.2003.10.036
18. van der Heijden AG, Kiemeney LA, Gofrit ON et al (2004) Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol 46:65-71. doi: 10.1016/ j.eururo.2004.01.019
19. Colombo R, Lev A, Da Pozzo LF, Freschi M, Gallus G, Rigatti P (1995) A new approach using local combined microwave hyperthermia and chemotherapy in superficial transitional bladder carcinoma treatment. J Urol 153:959-963. doi: 10.1016/S0022-5347(01)67613-4
20. Newling DW, Hetherington J, Sundaram SK, Robinson MR, Kisbenedek L (2001) The use of valrubicin for the chemoresection of superficial bladder cancer - a marker lesion study. Eur Urol 39:643-647. doi: 10.1159/000052521
21. Bartoletti R, Cai T, Gacci M et al (2005) Intravesical gemcitabine therapy for superficial transitional cell carcinoma: Results of a phase II prospective multicenter study. Urology 66:726-731. doi: 10.1016/ j.urology.2005.04.062
22. Dalbagni G, Russo P, Bochner B et al (2006) Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 24:2729-2734. doi: 10.1200/JCO.2005.05.2720
23. Sarosdy MF, Manyak MJ, Sagalowsky AI et al (1998) Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guerin. Urology 51:226-231. doi: 10.1016/ S0090-4295(97)00510-4
24. Joudi FN, Smith BJ, O'Donnell MA (2006) Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 24:344-348. doi: 10.1016/j.urolonc.2005.11.026
25. Waidelich R, Stepp H, Baumgartner R, Weninger E, Hofstetter A, Kriegmair M (2001) Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. J Urol 165:1904-1907. doi: 10.1016/S0022-5347(05)66239-8
26. Colombo R, Brausi M, Da PL et al (2001) Thermo-chemotherapy and electromotive drug administration of mitomycin C in superficial bladder cancer eradication: A pilot study on marker lesion. Eur Urol 39:95-100. doi: 10.1159/000052419
27. Malmstrom PU, Wijkstrom H, Lundholm C, Wester K, Busch C, Norlen BJ (1999) 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian bladder cancer study group. J Urol 161:1124-1127. doi: 10.1016/S0022-5347(01)61607-0
28. Hautmann RE, Stein JP (2005) Neobladder with prostatic capsule and seminal-sparing cystectomy for bladder cancer: A step in the wrong direction. Urol Clin North Am 32:177-185. doi: 10.1016/j.ucl.2005.02.001
29. Witjes JA, Kiemeney LA, Schaafsma HE, Debruyne FM (1994) The influence of review pathology on study outcome of a randomized multicentre superficial bladder cancer trial. Br J Urol 73:172-176. doi: 10.1111/ j.1464-410X.1994.tb07487.x